34 min
The Applications of Real-World Data in Biotech with Lana Denysyk Data in Biotech
-
- Life Sciences
This week, we’re delighted to be joined by Lana Denysyk, Head of RWD Assets at Novo Nordisk.
During this conversation, Lana shares how real-world data is used in biotech, diving into how it can help clinicians understand patient experiences outside clinical trials. Lana also discusses the challenges in acquiring and utilising real-world data, the importance of having a centralised team to manage it, and emerging data types like patient-reported outcomes and health equity data.
Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in life sciences.
Discussed:
[1:08] Lana talks about her career to date, from public health graduate to head of a real-world data department at Nova Nordisk.
[3:55] Ross and Lana break down exactly what real-world data means and how biotech organisations use it.
[7:03] Lana outlines that RWD is part of a diverse data ecosystem in organizations and why it's crucial to understand which data type best suits specific research questions to avoid silos and maximize data utilization.
[8:40] Lana gives examples of the types of stakeholder groups that have research questions where RWD is helpful.
[11:54] Lana walks through how she thinks about scoping a request for RWD and understanding the limitations and applicability of the data.
[17:36] Ross and Lana discuss the role of RWD professionals in facilitating broader access to data through platforms and tools for non-data scientists.
[19:33] Lana highlights why standardizing real-world data management processes, despite the diversity in data types, is crucial for efficiently integrating new data into an organization and what this process looks like.
[21:31] Lana discusses the role of GDPR and HIPAA and its impact on RWD.
[23:52] Lana discusses real-world data strategy in pharma, highlighting the importance of assessing data adequacy, employee training, and educating all staff on data capabilities and limitations for effective future use.
[29:10] Lana shares her excitement about emerging real-world data sets beyond traditional claims and EMR sources in pharma,
[32:30] Lana lists some resources people can use to stay up-to-date on the application of RWD in biotech.
---
If you’re a biotech company struggling to unlock a data challenge, CorrDyn can help.
Whether you need to supplement existing technology teams with specialist expertise or launch a data program that lays the groundwork for future internal hires, you can partner with Corrdyn to unlock the potential of your business data - today.
Visit connect.corrdyn.com/biotech to learn more.
This week, we’re delighted to be joined by Lana Denysyk, Head of RWD Assets at Novo Nordisk.
During this conversation, Lana shares how real-world data is used in biotech, diving into how it can help clinicians understand patient experiences outside clinical trials. Lana also discusses the challenges in acquiring and utilising real-world data, the importance of having a centralised team to manage it, and emerging data types like patient-reported outcomes and health equity data.
Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in life sciences.
Discussed:
[1:08] Lana talks about her career to date, from public health graduate to head of a real-world data department at Nova Nordisk.
[3:55] Ross and Lana break down exactly what real-world data means and how biotech organisations use it.
[7:03] Lana outlines that RWD is part of a diverse data ecosystem in organizations and why it's crucial to understand which data type best suits specific research questions to avoid silos and maximize data utilization.
[8:40] Lana gives examples of the types of stakeholder groups that have research questions where RWD is helpful.
[11:54] Lana walks through how she thinks about scoping a request for RWD and understanding the limitations and applicability of the data.
[17:36] Ross and Lana discuss the role of RWD professionals in facilitating broader access to data through platforms and tools for non-data scientists.
[19:33] Lana highlights why standardizing real-world data management processes, despite the diversity in data types, is crucial for efficiently integrating new data into an organization and what this process looks like.
[21:31] Lana discusses the role of GDPR and HIPAA and its impact on RWD.
[23:52] Lana discusses real-world data strategy in pharma, highlighting the importance of assessing data adequacy, employee training, and educating all staff on data capabilities and limitations for effective future use.
[29:10] Lana shares her excitement about emerging real-world data sets beyond traditional claims and EMR sources in pharma,
[32:30] Lana lists some resources people can use to stay up-to-date on the application of RWD in biotech.
---
If you’re a biotech company struggling to unlock a data challenge, CorrDyn can help.
Whether you need to supplement existing technology teams with specialist expertise or launch a data program that lays the groundwork for future internal hires, you can partner with Corrdyn to unlock the potential of your business data - today.
Visit connect.corrdyn.com/biotech to learn more.
34 min